12:00 AM
 | 
Mar 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NKTR-118: Phase II data

Nektar ended early a double-blind, placebo-controlled, dose-escalation, international Phase II trial in 208 patients with OIC based on a recommendation from an independent dose escalation committee after top-line data showed that 2 doses of NKTR-118 met the primary and secondary endpoints. On the primary endpoint, 25 and 50 mg oral NKTR-118 given once daily significantly increased...

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >